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Microvesicles and exosomes have emerged
as a new mode of intercellular communi-
cation in cancer. In recent years, microvesi-
cles have received increasing attention from
the scientific community for their role in
regulating and transferring active mole-
cules responsible for tumor progression
and metastasis. Controversy arises from
the fact that microvesicles can transfer
tumor-promoting molecules such as onco-
proteins (1–3), and tumor suppressors (4,
5). So, how can we make sense of this
controversy?
By considering what we know of cancer
development, we can rectify the seemingly
opposing findings of the role of microvesi-
cles in this process. The role of oncogenes
in the progression of cancer is a well-
investigated matter, and it is known that
cancer progression is dependent on over-
expression or mutation of oncogenic pro-
teins. On the other hand, it also depends on
loss or downregulation of tumor suppres-
sor proteins.
The effect of the intercellular exchange
of oncoproteins and tumor suppressor
proteins through microvesicles on can-
cer progression most probably follows the
“Yin–Yang” concept. The availability of
microvesicles rich in oncoproteins or those
containing tumor suppressors will decide
the new phenotype characteristics acquired
by the acceptor cells. In the case of the
tumor suppressor PTEN, it is interesting to
note that metastases often have no expres-
sion of PTEN, although the primary tumor
itself expresses PTEN (6). This may indi-
cate that cells capable of initiating metas-
tasis originate from cellular selection (7),
whereby cells with little or no expression
of PTEN are more likely to initiate suc-
cessful metastases (8, 9). Furthermore, it
is known from a series of studies of two
tumor systems that tumors “talk” to each
other through serum-borne factors (10–
12). A tumor at one side of an experimental
animal can affect the dynamics of a tumor
on the other side. However, the serum-
borne factors suggested in these studies are
not fully defined; microvesicles represent
a reasonable candidate as a player in this
form of cellular communication. Such a
mode of cellular communication may have
a role in tumor metastasis.
Microvesicles that contain PTEN are
shed from primary PTEN-expressing
tumors to the bloodstream, and may rep-
resent the serum-borne factors that are
used by the primary tumor to affect
the growth of metastases not express-
ing PTEN. This may indicate a suc-
cessfully adopted mechanism through-
out the natural history of cancer devel-
opment, in which PTEN-null cells in
the primary tumor form “tumor’s prog-
eny” in the form of metastases. These
metastases may be more aggressive than
the primary tumor, because they do
not express PTEN. The primary tumor
then controls the growth of its “prog-
eny” through tumor suppressor (PTEN)
enriched microvesicles, which circulate in
the blood and keep PTEN-null metas-
tases in dormancy by supplementing them
with PTEN protein. This hypothesis may
explain the known phenomenon in which
removal of the primary tumor enhances
the growth of metastases, because the
source of the PTEN-bearing microvesicles
is removed.
On the other hand, microvesicles
enriched with oncogenic proteins may
be shed by tumor cells to oppose the
increased metabolic demand associated
with overexpression of oncogenic proteins.
Oncogenic protein expressing microvesi-
cles are also used as intercellular media-
tors to engage other cells (which may be
healthy) to provide a suitable growth niche
to nourish cancer cells. For example,EGFR-
bearing microvesicles stimulate endothelial
cells to secrete vascular endothelial growth
factor (VEGF) and the autophosphoryla-
tion of the VEGF receptor-2 (VEGFR2),
triggering the angiogenic switch to initiate
angiogenesis (1).
It is noteworthy that microvesicles
also contribute to the transfer of other
molecules such as mRNAs and miRNA
(miR), which can have various effects on
tumor progression by modulating tumor
microenvironment. An interesting cross-
talk was found between hepatocarcinoma
cells, whereby cells expressing miR-122
send this miR via microvesicles to inhibit
the proliferation of miR-122 deficient cells.
In a reciprocal process, miR-122 defi-
cient cells secrete insulin-like growth factor
to decrease miR-122 expression in miR-
122 expressing cells (13). Microvesicles
from cancer cells are found to stimulate
tumor-associated macrophages to secrete
VEGF, through the transfer of miR-150
(14) and thereby enhance tumorigenic-
ity. In an opposite effect, macrophages
inhibit proliferation of hepatocarcinoma
cells by transferring miR-142 and miR-
223 via microvesicles (15). A similar
effect is found for microvesicles from
marrow stromal cells expressing miR-146,
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which inhibit the proliferation of glioma
cells (16).
In this sense, the role of microvesi-
cles that contain molecules whose effects
are seemingly in opposition (oncoproteins,
oncomirs, or tumor suppressors) may be
reconciled from the perspective of the
tumor, a successful parasitic organ gener-
ated from our own cells. We realize that
this commentary may contain some spec-
ulations, but we hope that it can trigger
serious discussions in tumor biology,which
may contribute to the long battle against
the killer known as cancer.
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